TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24944041
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with PF-04449913 (200 mg single dose)
Study: 24944041
Drug: PF-04449913 alone
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 alone (200 mg single dose)
Study: 22348605
Drug: Tapentadol 75
Normalized name: tapentadol 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol 75 mg t.d.s. for 48 h
Study: 22348605
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg t.d.s. for 48 h
Study: 9106787
Drug: 20% fat
Normalized name: Intralipid 20% Fat Emulsion for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% fat emulsion formulation
Study: 9106787
Drug: 2% formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% formulation enriched 10-fold with phospholipids
Study: 3520619
Drug: Local antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antibacterial agents (variety of local antibacterials)
Study: 3520619
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent povidone-iodine (50 percent Betadine) solution
Study: 30230266
Drug: Low-dose treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose treatment (150 M)
Study: 30230266
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment (300 M)
Study: 24462483
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg zinc sulfate for 14 days)
Study: 15468574
Drug: Albendazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (single dose)
Study: 23147875
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy every 2 hours (CPAP 2 hrs)
Study: 23147875
Drug: Incentive spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive spirometry (IS) therapy
Study: 23147875
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy every 4 hours (CPAP 4 hrs)
Study: 19280112
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg once daily for 2 weeks
Study: 19280112
Drug: Famotidine 10
Normalized name: famotidine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 10 mg twice daily for 2 weeks
Study: 19280112
Drug: Famotidine 10
Normalized name: famotidine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 10 mg twice daily for a third 2-week period
Study: 17192288
Drug: Tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 1.25 mg/d
Study: 17192288
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/d
Study: 17192288
Drug: CEE/MPA (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (0.625 + 2.5 mg/d)
Study: 10553738
Drug: Clozapine 100
Normalized name: clozapine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 100 mg/day
Study: 10553738
Drug: Clozapine 300
Normalized name: clozapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 300 mg/day
Study: 15365707
Drug: Haloperidol 10
Normalized name: haloperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10 mg/day (4-week trial)
Study: 9700674
Drug: Cerebrolysin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (10 ml, 30 ml)
Study: 9700674
Drug: Cerebrolysin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 50 ml
Study: 9700674
Drug: Cerebrolysin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (all doses)
Study: 8305754
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of EMLA cream
Study: 28265816
Drug: Morinidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morinidazole (500 mg twice daily for 14 days)
Study: 28265816
Drug: Ornidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole (500 mg twice daily for 14 days)
Study: 25540268
Drug: Inactivated whole‐virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole‐virus Vero cell culture‐derived RRV vaccine (2.5‐μg dose, Al(OH)(3)‐adjuvanted, with second and third doses after 3 weeks and 6 months)
Study: 25540268
Drug: Inactivated whole‐virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole‐virus Vero cell culture‐derived RRV vaccine
Study: 22957911
Drug: Platform-switched implant-abutment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implant-abutment connection (test)
Study: 22957911
Drug: Platform-matched implant-abutment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-matched implant-abutment connection (control)
Study: 16573800
Drug: Lansoprazole 60‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60‐mg intravenous bolus followed by 6‐mg/h continuous infusion
Study: 16573800
Drug: Lansoprazole 90‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 90‐mg intravenous bolus followed by 6‐mg/h continuous infusion
Study: 16573800
Drug: Lansoprazole 90‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 90‐mg intravenous bolus followed by 7.5‐mg/h continuous infusion
Study: 16573800
Drug: Lansoprazole 90‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 90‐mg intravenous bolus followed by 9‐mg/h continuous infusion
Study: 12452516
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metronidazole and povidone iodine
Study: 10511022
Drug: Brinzolamide 1%
Normalized name: BRINZOLAMIDE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 1% ophthalmic suspension
Study: 10511022
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% ophthalmic solution
Study: 2387667
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 mg twice daily for 4 weeks)
Study: 6122232
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg propoxyphene napsylate (PN) in two divided doses
Study: 6122232
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg methadone
Study: 8498759
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methadone
Study: 25770879
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate gel (0.015% once daily for 3 days for face/scalp; 0.05% once daily for 2 days for trunk/extremities)
Study: 22417254
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate gel
Study: 25199059
Drug: Intravenous mepolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mepolizumab (75 mg every 4 weeks for 32 weeks)
Study: 25199059
Drug: Subcutaneous mepolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous mepolizumab (100 mg every 4 weeks for 32 weeks)
Study: 21114680
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (non-surgical periodontal therapy)
Study: 20544030
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (control group)
Study: 19526589
Drug: Interferon-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (3 million U subcutaneously 3x weekly, escalating to 18 MU)
Study: 17511767
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg/day for 4 weeks increased to 120 mg/day for 8 weeks
Study: 16493377
Drug: Hypocaloric balanced
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric balanced diet therapy with antioxidant and ω-3 supplementation
Study: 16493377
Drug: Hypocaloric balanced
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric balanced diet therapy
Study: 3610329
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) injection of 1 g cefpirome
Study: 3610329
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection of 1 g cefpirome
Study: 3610329
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) and Intramuscular (i.m.) injections of 1 g cefpirome
Study: 25352437
Drug: 2RDA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2RDA (1.5 g·kg(‐1)·day(‐1))
Study: 25352437
Drug: 1RDA (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1RDA (0.8 g·kg(‐1)·day(‐1))
Study: 19342506
Drug: Pexacerfont 25
Normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexacerfont 25 mg qd
Study: 19342506
Drug: Pexacerfont 100
Normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexacerfont 100 mg qd
Study: 16478794
Drug: Etoposide-cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etoposide-cisplatin chemotherapy
Study: 15270741
Drug: Family unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family unit treatment (all infected family members treated)
Study: 15270741
Drug: Index case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index case treatment (index case only treated)
Study: 10985630
Drug: Nickel sulfate
Normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulfate patch tests at 1, 3, and 7 cm distance from potassium dichromate patches
Study: 10985630
Drug: Nickel sulfate
Normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulfate patch tests at 1 cm distance from potassium dichromate patches
Study: 10985630
Drug: Nickel sulfate
Normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulfate patch tests
Study: 7510736
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg)
Study: 8364286
Drug: Antimicrobial drugs
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial drugs (AMDs) prescribed to hospitalized children
Study: 3511372
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide plus low-dose prednisone
Study: 3511372
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral prednisone alone
Study: 1412641
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg body weight)
Study: 3293827
Drug: Amodiaquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (25 mg/kg)
Study: 3293827
Drug: Sulfadoxine‐pyrimethamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (25 mg/kg and 1.25 mg/kg)
Study: 3293827
Drug: Amodiaquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (25 mg/kg) + sulfadoxine‐pyrimethamine (25 mg/kg and 1.25 mg/kg)
Study: 25138579
Drug: Tamsulosin OCAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin OCAS 0.4 mg and desmopressin MELT 60 mcg (D/T group)
Study: 25138579
Drug: Tamsulosin OCAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin OCAS 0.4 mg only (T group)
Study: 22802301
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (with antidepressants)
Study: 21791883
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VerifyNow P2Y12 (PRU) and Aspirin (ARU) testing
Study: 17361920
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg/day orally
Study: 17361920
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy (bicalutamide)
Study: 2877131
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone substitution therapy (TTS)
Study: 29178769
Drug: Desensitizing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing agents (five commercially available agents applied according to manufacturers' instructions)
Study: 29178769
Drug: Desensitizing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing agents (five commercially available agents)
Study: 25100892
Drug: Caffeine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.5 mg/kg)
Study: 25100892
Drug: Maltodextrin (CHO)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (CHO) (1 g/kg)
Study: 22888676
Drug: Probiotic cheese
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic cheese comprising L. plantarum TENSIA (DSM 21380) consumed for 3 weeks
Study: 22888676
Drug: Probiotic cheese
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic cheese comprising L. plantarum TENSIA (DSM 21380)
Study: 10534516
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy, 3 x 10(6) U s.c., three times a week (post-HD)
Study: 2270581
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg OTC three times/day
Study: 19883809
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin (group A)
Study: 11477461
Drug: High group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High group (500 g/day fruit and vegetables and 200 ml/day fruit juice)
Study: 11477461
Drug: Low group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low group (100 g/day fruit and vegetables)
Study: 8206395
Drug: Octreotide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (single injection)
Study: 31563344
Drug: Ceftolozane-tazobactam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane-tazobactam (3 g intravenously every 8 h for 8-14 days)
Study: 31563344
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g intravenously every 8 h for 8-14 days)
Study: 23660721
Drug: Distributed training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed training group with five monthly unsupervised training sessions of 30 min on a box trainer (group 3)
Study: 23660721
Drug: Distributed training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed training group with five monthly unsupervised training sessions of 30 min on the LapMentor(®) (group 4)
Study: 22057609
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing plus photodynamic therapy (Sc/Rp + PDT)
Study: 18845008
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Cognitive Behavioral Therapy (CBT)
Study: 12878920
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Cognitive Behavioral Therapy (CBT)
Study: 15293581
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous morphine and procedural information
Study: 15293581
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous ketorolac and procedural information
Study: 15293581
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous morphine plus procedural and sensory information
Study: 15293581
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous ketorolac plus procedural and sensory information
Study: 15293581
Drug: All interventions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All interventions (morphine and ketorolac)
Study: 8089357
Drug: Topical EMLA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EMLA
Study: 9417009
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo (no anesthetic)
Study: 7619991
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of fluconazole (group B)
Study: 7619991
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous administration of amphotericin B (group C)
Study: 2571625
Drug: Trauma desensitization,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma desensitization, hypnotherapy, and psychodynamic therapy
Study: 346292
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or Placebo
Study: 28646812
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 supplementation (300 mg/d for weeks 1-4, 150 mg/d for weeks 5-8)
Study: 28646812
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rice flour placebo, similar dosing to intervention group)
Study: 11303598
Drug: N-acetylcysteine/oltipraz (NAC/OLZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine/oltipraz (NAC/OLZ) combination, OLZ 200 mg (Arm B)
Study: 11303598
Drug: N-acetylcysteine/oltipraz (NAC/OLZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine/oltipraz (NAC/OLZ) combination, OLZ 400 mg (Arm C)
Study: 11303598
Drug: N-acetylcysteine/oltipraz (NAC/OLZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine/oltipraz (NAC/OLZ) combination, placebo (Arm A)
Study: 11303598
Drug: N-acetylcysteine/oltipraz (NAC/OLZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine/oltipraz (NAC/OLZ) combination
Study: 8884875
Drug: Clodronate (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (800 mg orally four times daily)
Study: 8884875
Drug: Estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estramustine phosphate (280 mg orally twice daily)
Study: 1669598
Drug: Local immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local immunotherapy (LI) by inhalation of a powder extract of house dust mite (HDM)
Study: 1669598
Drug: Parenteral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral immunotherapy (PI) by injection
Study: 6601670
Drug: SRW intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRW intranasal immunotherapy (n = 11); cumulative AgE doses from 3 to 59 micrograms (mean 21)
Study: 30840130
Drug: Uninterrupted apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Uninterrupted apixaban therapy (Group 1, n=32)
Study: 30840130
Drug: Interrupted apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interrupted apixaban therapy (Group 2, n=65)
Study: 29235300
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine and Western medicine treatment (Buxin Yishen decoction)
Study: 29235300
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine treatment (control group)
Study: 24435207
Drug: Silodosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin (8 mg/day for 6 months)
Study: 19079954
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment combined with cognitive-behavioral therapy (CBT)
Study: 11719017
Drug: Eudragit L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eudragit L 30 D‐55 coated capsules
Study: 11719017
Drug: Eudragit FS
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eudragit FS 30 D coated capsules
Study: 9620358
Drug: Anti-CD3 monoclonal
Normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD3 monoclonal antibody (mAb) OKT3 and phorbol myristate acetate (PMA) stimulation in young humans
Study: 9620358
Drug: Anti-CD3 monoclonal
Normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD3 monoclonal antibody (mAb) OKT3 and phorbol myristate acetate (PMA) stimulation in elderly humans
Study: 7616847
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous Intralipid infusion (test 1)
Study: 7616847
Drug: Heparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (30 U/min) plus low-dose Intralipid infusion (test 2)
Study: 10532694
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion
Study: 1969013
Drug: Heparin bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bolus
Study: 6448885
Drug: L-Deprenil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Deprenil plus L-5-HTP and benzerazide
Study: 6448885
Drug: L-5-HTP and
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-HTP and benzerazide
Study: 29081098
Drug: Alanyl glutamine
Normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl glutamine injection plus conventional therapy
Study: 26480877
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 2 g by topical application
Study: 23596780
Drug: Shenyan Kangfu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyan Kangfu Tablet (SKT)